Real-life experience with benralizumab during 6 months

BACKGROUND: Benralizumab is a monoclonal antibody that binds to the human interleukin-5 (IL-5) receptor (IL-5R), thereby preventing IL-5 from binding to its receptor and inhibiting differentiation and maturation of eosinophils in the bone marrow. Because of its recent marketing approval, sufficient...

Descripción completa

Detalles Bibliográficos
Autores principales: Padilla-Galo, A., Levy-Abitbol, RCh, Olveira, C., Valencia Azcona, B., Pérez Morales, M., Rivas-Ruiz, F., Tortajada-Goitia, B., Moya-Carmona, I., Levy-Naon, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325276/
https://www.ncbi.nlm.nih.gov/pubmed/32600318
http://dx.doi.org/10.1186/s12890-020-01220-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325276/
https://www.ncbi.nlm.nih.gov/pubmed/32600318
http://dx.doi.org/10.1186/s12890-020-01220-9

Ejemplares similares